Citations

Mayo Clinic

Clear

15 citation(s) found for "Yin, Ping".

Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer
Zhou, Qin, Dibbs, Anna, Yin, Ping, Pavelko, Kevin D. , Dong, Haidong , Luo, Kuntian, Tu, Xinyi , Lucien, Fabrice , Park, Sean S. , Grams, Michael P. , Xu‐Welliver, Meng , Callaghan, Cameron , Lou, Zhenkun, Mutter, Robert W., Han, Yiqun , Zhu, Shouhai , Yin, Ping, Lou, Zhenkun , Mutter, Robert W. , Lucien-Matteoni, Fabrice

Frontiers in Immunology | September 18, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1929236 | PMID 42827904 Get It

Introduction Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase involved in immune signaling and has been implicated in tumor-intrinsic resistance to DNA-damaging therapies. Although SYK activity has been associated with poor outcomes in triple-negative breast cancer (TNBC), its role in resistance to combined radiotherapy and immune checkpoint blockade remains unclear. Methods SYK expression and clinical relevance were assessed across multiple breast cancer cohorts, including radiotherapy-treated datasets. Integrated transcriptomic analyses were used to characterize SYK-associated immune states. The functional effects of pharmacologic SYK inhibition were evaluated using in vitro assays and an immunocompetent bilateral 4T1 tumor model in female BALB/c mice treated with radiotherapy and PD-1 blockade. Treatment-associated immune remodeling was assessed by flow cytometry and transcriptomic profiling. Results Across multiple cohorts, elevated SYK expression, particularly in TNBC, was associated with inferior clinical outcomes and immune dysregulation. Pharmacologic SYK inhibition enhanced tumor responses to radiotherapy and PD-1 blockade at both irradiated and distant tumor sites. These effects were accompanied by coordinated remodeling of the tumor immune microenvironment, including suppression of neutrophil-associated signatures and reductions in immunosuppressive myeloid populations, including M2-like macrophages and myeloid-derived suppressor cells. Discussion Pharmacologic SYK inhibition enhances responses to radiotherapy and PD-1 blockade in preclinical TNBC models and is accompanied by remodeling of the immunosuppressive myeloid compartment. These findings support further investigation of SYK-targeted strategies to improve responses to combined radiotherapy and immune checkpoint blockade.
ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression
Tu, Xinyi , 孙要良, Ouyang, Yaobin, Zhu, Lingling, Pavelko, Kevin D. , Leon-Ferre, Roberto A., Jiang, Yanxia , Dong, Haidong , Sarkaria, Jann N., Wang, Liewei , Huang, J, Luo, Kuntian, Mutter, Robert W. , Pavelko, Kevin D , Dong, Haidong , Zeng, Xiangyu , Ouyang, Yaobin , Yin, Ping , Carter, Jodi M. , Zhu, Shouhai , Sarkaria, Jann N. , Han, Yiqun , Wu, Zheming , Lou, Zhenkun

Journal of Clinical Investigation | July 7, 2026 | Volume: 136 | Issue: 16 | Pages: No page available

10.1172/jci192285 | PMID 42412560 Get It

Our research uncovers a role for ATR in responding to ECM stiffness and promoting epithelial-to-mesenchymal transition (EMT) and metastasis. ATR, when deubiquitinated and upregulated by USP21 under enhanced ECM stiffness conditions, phosphorylates the nuclear protein SUN2, which promotes β-catenin nuclear translocation and EMT. ATM-mediated EMT promotes polymorphonuclear myeloid-derived suppressor cell recruitment and inhibits CD103 + dendritic cells, fostering an immunosuppressive tumor milieu. ATR inhibition disrupts this malignant cascade by promoting mesenchymal-to-epithelial transition to enhance antitumor immunity and mitigate metastases. Consistently, circulating HLA-DR + dendritic cells were also enhanced following treatment with the ATR inhibitor berzosertib in patients with therapeutically resistant early-stage breast cancer. Our data suggest that ATR-targeted therapy may be optimized by considering both DNA damage–dependent and EMT-inducing effects of ATR ATR promotes metastasis and immunosuppression through EMT process
Abstract 539: Cholesterol triggers chromatin stress to drive senescence and inflammation.
Han, Yiqun, Ouyang, Yaobin, Xu, Hangcheng, Chen, Bin, Yin, Ping , Zhou, Qin , Huang, Jinzhou , Luo, Kuntian, Wu, Zheming , Xiao, Huaping, Tu, Xinyi , Jing, Jiajun, Huang, Xiaofeng, Welliver, M.X., Lou, Zhenkun, Mutter, Robert, Ouyang, Yaobin , Zhu, Shouhai , Xu, Hangcheng , Yin, Ping, Huang, Jinzhou, Kloeber, Jake A. , Lou, Zhenkun , Mutter, Robert W.

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 539-539

10.1158/1538-7445.am2026-539 Get It

Abstract Cholesterol has long been viewed as a structural component of cellular membranes, yet its role in DNA damage response remains poorly defined. Here, we show that ionizing radiation (IR) induces broad transcriptional upregulation of cholesterol biosynthesis, transport, and storage pathways, leading to sustained intracellular accumulation of cholesterol. BODIPY-cholesterol imaging, Filipin III staining, and quantitative subcellular fractionation confirmed selective nuclear enrichment of cholesterol following IR, coinciding with extensive chromatin remodeling. Proteomic profiling of cholesterol-interacting proteins revealed a strong enrichment of chromatin-associated factors, suggesting a previously unrecognized lipid-chromatin interface in irradiated cells. Functionally, cholesterol accumulation promoted chromatin compaction and repressive histone modification patterns, impairing DNA damage sensing and checkpoint activation despite increased underlying DNA lesions. These alterations facilitated aberrant mitotic entry, formation of cytoplasmic chromatin fragments (CCFs), and activation of cGAS-STING-NF-κB signaling. Cholesterol exposure ultimately diverted damaged cells toward a senescent fate, marked by Lamin B1 loss, p21 induction, and a robust senescence-associated secretory phenotype (SASP) enriched for IL-1 and TNF family cytokines. In vivo, dietary cholesterol exacerbated radiation-induced inflammation and weakened systemic anti-tumor immunity. Transcriptomic analyses of immunotherapy-treated patients revealed that tumors enriched for cholesterol import and senescence signatures were associated with poor response to PD-L1 blockade and worse survival. Together, these findings identify a cholesterol-chromatin-senescence axis that links metabolic remodeling to defective DNA damage signaling and immune suppression after radiation, highlighting cholesterol metabolism as a potential therapeutic vulnerability in cancer therapy. Citation Format: Yiqun Han, Yaobin Ouyang, Shouhai Zhu, Hangcheng Xu, Bin Chen, Ping Yin, Qin Zhou, Jinzhou Huang, Kuntian Luo, Zheming Wu, Huaping Xiao, Xinyi Tu, Jake A. Kloeber, Jiajun Jing, Xiaofeng Huang, Meng Xu Welliver, Zhenkun Lou, Robert Mutter. Cholesterol triggers chromatin stress to drive senescence and inflammation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 539.
Parkin deficiency promotes colorectal tumorigenesis and progression through RIPK3‐dependent necroptotic inflammation
Wu, Zheming , Xiao, Huaping, Ouyang, Yaobin , Yin, Ping , Huang, Jinzhou , Lu, Jing , Tu, Xinyi , Ting, Adrian T. , Welliver, M.X., Lou, ZhenkunLou, Zhu, Shouhai , Dragojevic, Sonja , Lou, Zhenkun , Welliver, Meng, Kloeber, Jake A. , Chen, Bin, Han, Yiqun

Cancer Communications | January 4, 2025 | Volume: 45 | Issue: 4 | Pages: 406-410

10.1002/cac2.12648 | PMID 39754711 Get It

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer
Huang, Minhong , Gao, Huanyao , Kim, Wootae , John, August , Weinshilboum, Richard M. , Wang, Liewei , Xie, Fang , Gao, Huanyao , Kim, Wootae , John, August , Qin, Sisi , Xie, Fang , Yin, Ping , Weinshilboum, Richard M.

Cells | September 30, 2024 | Volume: 13 | Issue: 19 | Pages: 1622

10.3390/cells13191622 | PMID 39404386 Get It

Most patients with metastatic prostate cancer eventually develop resistance to primary androgen deprivation therapy. To identify predictive biomarker for Abiraterone acetate/prednisone resistance, we screened alternative splice variants between responders and non-responders from the PROMOTE clinical study and pinned down the most significant variant, CENPK–delta8. Through preclinical patient-derived mouse xenograft (PDX) and 3D organoids obtained from responders and non-responders, as well as in vitro models, aberrant CENPK–delta8 expression was determined to link to drug resistance via enhanced migration and proliferation. The FLNA and FLOT1 were observed to specifically bind to CENK–delta8 rather than wild-type CENPK, underscoring the role of CENPK–delta8 in cytoskeleton organization and cell migration. Our study, leveraging data from the PROMOTE study, TCGA, and TCGA SpliceReq databases, highlights the important function of alternative splice variants in drug response and their potential to be prognostic biomarkers for improving individual therapeutic outcomes in precision medicine.
Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
Gao, Huanyao , Kim, Wootae , Scholz, Jodi A. , Yu, Jia , Qin, Bo , Zhuang, Yongxian , Tan, Winston , Bryce, Alan H. , Weinshilboum, Richard M. , Wang, Liewei , Xie, Fang , Bryce, Alan H , Kim, Wootae , Qin, Sisi , Zhang, Huan , Gu, Yayun , Kalari, Krishna R. , Sinnwell, Jason P. , Xie, Fang , Yin, Ping , Wei, Lixuan , Weinshilboum, Richard M.

Clinical Pharmacology & Therapeutics | March 15, 2022 | Volume: 111 | Issue: 6 | Pages: 1296-1306

10.1002/cpt.2582 | PMID 35288936 Get It

Approximately one‐third of patients with metastatic castration‐resistant prostate cancer (CRPC) exhibited primary abiraterone resistance. To identify alternative treatment for abiraterone nonresponders, we performed drug discovery analyses using the L1000 database using differentially expressed genes identified in tumor biopsies and patient‐derived xenograft (PDX) tumors between abiraterone responders and nonresponders enrolled in PROMOTE trial. This approach identified 3 drugs, including topoisomerase II (TOP2) inhibitor mitoxantrone, CDK4/6 inhibitor palbociclib, and pan‐CDK inhibitor PHA‐793887. These drugs significantly suppressed the growth of abiraterone‐resistant cell lines and PDX models. Moreover, we identified 11 genes targeted by all 3 drugs that were associated with worse outcomes in both the PROMOTE and Stand Up To Cancer cohorts. This 11‐gene panel might also function as biomarkers to select the 3 alternative therapies for this subgroup of patients with CRPC, warranting further clinical investigation.
Temporal analysis of signaling pathways associated with the development of renovascular hypertension
Grande, Joseph P. , Zhou, Wei , Warner, Gina M., Gray, Catherine , Cheng, Jingfei , Yin, Ping

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.1210.3 Get It

The objective of this study was to identify signaling pathways leading to the development of interstitial fibrosis and tubular atrophy in the stenotic kidney and compensatory hypertrophy/hyperplasia of the contralateral kidney in a murine 2 kidney 1 clip model of hypertensive nephrosclerosis. Mice were studied 2, 5, and 11 weeks after undergoing surgery to establish unilateral renal artery stenosis (RAS). RAS animals, but not sham controls, became hypertensive within 1 week. Compensatory enlargement of the contralateral kidney was associated with a transient increase in proliferation (as assessed by PCNA and Mib‐1), p‐ERK, caspase 3, p27, p53, and TGF‐β expression at early time points, with return to baseline levels by 11 weeks. Tubular atrophy in the stenotic kidney was associated with a persistent increase in p‐ERK, Mib‐1, p53, p21, and p27 expression through 11 weeks. Proliferative activity was observed in tubular epithelial cells and in inflammatory cells. The atrophic kidneys had little apoptotic activity (caspase 3, TUNEL staining). The atrophic kidneys showed progressive increases in TGF‐β and α‐SMA expression and extracellular matrix deposition throughout 11 weeks. Interstitial inflammation was associated with increased MCP‐1 expression. Mechanisms underlying this differential response to unilateral RAS await definition.
Pentoxifylline (PTX) ameliorates acute renal ischemia‐reperfusion (IR) injury
Grande, Joseph P. , Cheng, Jingfei , Yin, Ping

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.565.16 Get It

We have previously demonstrated that, in vitro, c‐AMP specific PDE3 inhibitors block mitogenesis of mesangial cells (Am J Physiol Renal Physiol, 2004) and PDE4 inhibitors block cytokine stimulated MCP‐1 expression (Am J Physiol Cell Physiol, 2005). The in vivo relevance of these findings has not been previously established. Mice were treated with the nonselective cAMP PDE inhibitor pentoxifylline (PTX) prior to bilateral clamping of the renal arteries for 30 minutes, followed by reperfusion for 1 and 4 days. PTX blunted the increase in BUN and creatinine after 1 day (−38% and −43%, respectively, p<0.05), and after 4 days (−80% and −44%, respectively, p<0.05). PTX reduced the extent of tubular necrosis (1 day: 39.13% vs. 52.5%; 4 days: 2.5% vs. 23.33%, p<0.05, p=NS. % cortical area in PTX vs. IR). PTX reduced PCNA expression 4 days after IR, as assessed by Western blot (−43%, p<0.05), and reduced caspase 3 activity one day after IR (−43%, p<0.05). PTX markedly reduced expression of MMP10 and Cox‐2 one day after IR (26 and 4 folds, respectively, p<0.05), which are induced in response to acute inflammation. PTX significantly reduced cyclin F, cyclin A2 and Ki67 expression 4 days after IR (124, 7 and 9 folds, respectively, p<0.05), which are induced in response to proliferation. We conclude that PTX ameliorates IR injury through c‐AMP mediated reduction in proliferative and inflammatory responses to acute injury.
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING
Yang, Qifan, Zeng, Xiangyu , Wang, Manxiang , Tu, Xinyi , Wei, Ting , Xie, Wenzhuan , Guo, Qiang , Kloeber, Jake A. , Cao, Yueyu, Guo, Guijie , Zhou, Qin , Huang, Jinzhou , Zhang, Kai , Luo, Kuntian, Kim, Wootae , Hou, Jing , Shi, Yu , Zhu, Qian , Hu, Sheng , Yue, Junqiu , Pi, Guoliang , Kloeber, Jake A , Liu, Li , Kim, Wootae , Zhu, Qian , Wei, Ting , Zeng, Xiangyu , Zhang, Yong , Dong, Shuang , Yang, Bin , Zhang, Chao , Zhao, Fei Linda , Liu, Li , Wang, Mingwei , Yin, Ping , Deng, Min , Chen, Lifeng , Lou, Zhenkun , Guo, Guijie

Cancer Discovery | June 7, 2021 | Volume: 11 | Issue: 11 | Pages: 2726-2737

10.1158/2159-8290.cd-20-1500 | PMID 34099454 Get It

Abstract Immune checkpoint blockade (ICB) has revolutionized cancer therapy. However, the response of patients to ICB is difficult to predict. Here, we examined 81 patients with lung cancer under ICB treatment and found that patients with MET amplification were resistant to ICB and had a poor progression-free survival. Tumors with MET amplifications had significantly decreased STING levels and antitumor T-cell infiltration. Furthermore, we performed deep single-cell RNA sequencing on more than 20,000 single immune cells and identified an immunosuppressive signature with increased subsets of XIST- and CD96-positive exhausted natural killer (NK) cells and decreased CD8+ T-cell and NK-cell populations in patients with MET amplification. Mechanistically, we found that oncogenic MET signaling induces phosphorylation of UPF1 and downregulates tumor cell STING expression via modulation of the 3′-UTR length of STING by UPF1. Decreased efficiency of ICB by MET amplification can be overcome by inhibiting MET. Significance: We suggest that the combination of MET inhibitor together with ICB will overcome ICB resistance induced by MET amplification. Our report reveals much-needed information that will benefit the treatment of patients with primary MET amplification or EGFR–tyrosine kinase inhibitor resistant-related MET amplification. This article is highlighted in the In This Issue feature, p. 2659
DOCK7 protects against replication stress by promoting RPA stability on chromatin
Gao, Ming , Guo, Guijie , Huang, Jinzhou , Hou, Xiaonan , Ham, Hyoungjun , Kim, Wootae , Tu, Xinyi , Zhou, Qin , Zhang, Chao , Zhu, Qian , Liu, Jiaqi , Xu, Zhijie , Luo, Kuntian, Weroha, S. John , Billadeau, Daniel D. , Yan, Yuanliang, Weroha, John, Kim, Wootae , Xu, Zhijie , Zhao, Fei , Yan, Yuanliang , Yin, Ping , Deng, Min , Lou, Zhenkun , Guo, Guijie

Nucleic Acids Research | March 2, 2021 | Volume: 49 | Issue: 6 | Pages: 3322-3337

10.1093/nar/gkab134 | PMID 33704464 Get It

Abstract RPA is a critical factor for DNA replication and replication stress response. Surprisingly, we found that chromatin RPA stability is tightly regulated. We report that the GDP/GTP exchange factor DOCK7 acts as a critical replication stress regulator to promote RPA stability on chromatin. DOCK7 is phosphorylated by ATR and then recruited by MDC1 to the chromatin and replication fork during replication stress. DOCK7-mediated Rac1/Cdc42 activation leads to the activation of PAK1, which subsequently phosphorylates RPA1 at S135 and T180 to stabilize chromatin-loaded RPA1 and ensure proper replication stress response. Moreover, DOCK7 is overexpressed in ovarian cancer and depleting DOCK7 sensitizes cancer cells to camptothecin. Taken together, our results highlight a novel role for DOCK7 in regulation of the replication stress response and highlight potential therapeutic targets to overcome chemoresistance in cancer.